Cycloserine
| DRUG INFORMATION |
| Drug Name |
| Cycloserine |
 |
| Synonyms |
| orientomycin, cycloserine, Seromycin, D-cycloserine, L-Cycloserine, Farmiserina, Cycloserin, Tebemicina, Novoserin, Miroseryn |
| Drug Class |
| Second-Line Drugs |
| Year of Introduction |
| 1955 |
| Molecular Target |
| Cell wall Synthesis |
| Genes Involved in Drug Resistance |
| ? |
| CAS No: |
| 68-41-7 |
| PHARMACOLOGY |
| Route |
| oral |
| Side effects |
| Frequent: CNS-anxiety, confusion, somnolence, disorientation, headache, hallucinations, tremor, hyperreflexia, increased CSF protein and pressure(dose related and reversible);severe depression w/ suicidal ideation. Sz (dose dependent, 3% w/ |
| Toxicity |
| High |
| Cost |
| High |
| Usual Adult Dosage |
| 10-15mg/kg qd (max 1000mg), usually 500-750 mg per day given in two divided doses. Serum concentration monitoring (goal peak): 20-35 mg/ml. |
| Form |
| cap |
| Brand Name |
| Seromycin |
| Manufacturer |
| Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA, Phone: +1-317-276-2000 |
| STRUCTURAL DETAILS |
| Molecular Formula |
| C3H6N2O2 |
| Molecular Weight in g/mol |
| 102.092 |
| Hydrogen Bond Donor Count |
| 2 |
| Hydrogen Bond Acceptor Count |
| 3 |
| Rotatable Bond Count |
| 0 |
| IUPAC Name |
| 4-aminoisoxazolidin-3-one |
| SMILES |
| C1C(C(=O)NO1)N |
| InChI |
| 1/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/f/h5H |
New Search